Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.56, read 2026-11-02
Ethical does not pass the values gate
Price37.17 USD
Fair value50.00
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-26Read Markup36.84+0.9% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-22Read Accumulation36.84+0.9% to today ✓Distribution gives way to Accumulation after a 5% rise in 11 days
2026-10-11Read Distribution35.05+6.0% to today Markdown gives way to Distribution first Distribution read since July
2026-10-02Read Markdown35.05+6.0% to today Accumulation gives way to Markdown after an 8% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
KBR, Inc. holds its Markup at $37.17. The statistical read favours the buyers, held for 46 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 46 days
Price at the screen
$37.17
Valuation
11.52 trailing · 9.86 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.44
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
43.86%
Below 33%
Interest-bearing debt is 43.9% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
23.30%
Below 49%
Money owed to the company is 23.3% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
KBR,'s business is in a permissible area, but its interest-bearing debt is about 44% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KBR's ethical verdict changes
Today KBR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 24% discount to our $50.00 fair value, 5.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 25.7% discount to the base estimate.
Where our models see it going: fair-value estimate $50.00, with a range of $50.00 to $76.08, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Government work rarely grows when budgets tighten
Governments still need engineering brains for bases, energy projects and defence kit. KBR sits inside that flow, turning specialist know-how into steady contracts across two main divisions. Yet revenue is already shrinking five percent, which undercuts any story of reliable expansion.
The forward multiple sits at just eight point five times, profit margins are thin at five percent, and return on equity looks healthy at twenty nine percent. Our own valuation sits well above the current price, but we still pass. Negative top-line momentum in a cyclical sector usually signals peak earnings rather than a bargain.
Currency swings, contract delays and sudden spending cuts remain real threats even after the ethical screen clears. Analyst targets cluster around forty five dollars, yet the business shows no clear path to sustained growth. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KBR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$39.64+1.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47.
2026-10-29Markup$39.23+6.5%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup$36.84+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$36.84+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup · changed$36.84+0.0%Entry 13
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$36.84+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$36.84+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$36.84+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$35.41+1.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (7 analysts) rates it buy, with a mean price target of $47.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
